ADA urges companies to issue data on incretin treatments

06/17/2013 | MedPage Today (free registration)

The American Diabetes Association has called on manufacturers of incretin therapies to disclose all patient-level data on their products for an independent analysis that would help determine if such treatments play a role in pancreatic cancer. AstraZeneca and Bristol-Myers Squibb expressed support for the ADA's call, noting in a joint statement that they look forward to a discussion with the group about its proposal.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Eastern Zone Sales Director
Regenesis Biomedical
White Plains, NY
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Associate Director, Regulatory Affairs - Promotional Review
Novo Nordisk
Princeton, NJ